I. Introduction: A Historic Year for Chinese Drugs at FDA
In 2026, Chinese innovative drugs achieved a series of historic milestones at the U.S. Food and Drug Administration (FDA). From anesthetics to insulin, Chinese-developed therapies are no longer just being licensed to global pharma — they are receiving direct FDA approval and entering the U.S. market under their own brand names.
This article reviews the most significant FDA approvals and regulatory milestones for Chinese drugs in 2026, including Cypsedo® (ciprofol), the first Chinese-developed anesthetic approved by the FDA, and Langlara® (insulin glargine), the first Chinese insulin to enter the U.S. market with an interchangeable designation.
II. Cypsedo® (Ciprofol) – China's First FDA-Approved Self-Developed Anesthetic
On May 29, 2026, the U.S. FDA approved Cypsedo® (ciprofol injection) for the induction of general anesthesia in adults — making it the first Chinese自主研发 intravenous anesthetic to receive FDA approval and the first Chinese innovative drug in the non-oncology field to be approved by the FDA.
Drug Overview
| Aspect | Details |
|---|---|
| Product Name | Cypsedo® (ciprofol injection) |
| Developer | Haisco Pharmaceutical (海思科) |
| Indication | Induction of general anesthesia in adults |
| Approval Date | May 29, 2026 |
| Significance | First Chinese self-developed anesthetic approved by FDA |
Clinical Significance
Ciprofol is a novel intravenous anesthetic with a mechanism of action similar to propofol — the current global standard — but with improved pharmacokinetic properties. Clinical trials demonstrated:
- Rapid onset: Induction of anesthesia within 30–60 seconds
- Faster recovery: Shorter awakening time compared to propofol
- Reduced injection pain: Significantly lower incidence of injection site pain — a common side effect of propofol
- Favorable safety profile: Comparable to propofol with no unexpected adverse events
Strategic Partnership with Eli Lilly
Immediately following the FDA approval, Haisco announced a strategic collaboration with Eli Lilly and Company valued at up to $3.054 billion. Under the agreement, Lilly will commercialize Cypsedo® in the U.S. and select international markets, leveraging its global anesthesia and hospital sales infrastructure.
This partnership validates the quality of Chinese innovation and provides a clear path to market for future Chinese anesthetic candidates.
III. Langlara® (Insulin Glargine) – China's First Insulin Enters the U.S. Market
On April 29, 2026, the FDA approved Langlara® (insulin glargine), developed by Sunshine Lake Pharma (a subsidiary of HEC Group / 东阳光药), for the treatment of type 1 and type 2 diabetes mellitus. Langlara® is the first Chinese-developed insulin approved in the United States and the fourth insulin glargine product marketed in the U.S.
Drug Overview
| Aspect | Details |
|---|---|
| Product Name | Langlara® (insulin glargine) |
| Developer | Sunshine Lake Pharma / HEC Group (东阳光药) |
| Indication | Type 1 and type 2 diabetes mellitus |
| Approval Date | April 29, 2026 |
| Key Designation | Interchangeable (可互换) – first Chinese insulin with this designation |
What "Interchangeable" Means
The FDA granted Langlara® the "Interchangeable" designation — a distinction reserved for biosimilar products that can be substituted for the reference product (Lantus®) without the intervention of the prescribing healthcare provider. This means:
- Pharmacies in the U.S. can automatically substitute Langlara® for Lantus® at the point of dispensing
- This is the fastest pathway to market penetration for biosimilars in the U.S.
- Langlara® is the fourth insulin glargine product with interchangeable status in the U.S.
Manufacturing and Supply
In July 2026, HEC Group announced the first shipment of 1.152 million vials of Langlara® from its Yidu manufacturing base (Hubei Province) to the United States. This marks the first commercial export of Chinese insulin to the U.S. market — a historic moment for China's biopharmaceutical manufacturing sector.
IV. Other 2026 FDA Milestones for Chinese Biopharma
BeiGene – Continued Global Expansion
Zanubrutinib (Brukinsa®), BeiGene's BTK inhibitor, continues to expand its global footprint. In 2026, the drug received additional FDA approvals for new indications, including:
- New combination regimens for chronic lymphocytic leukemia (CLL)
- Expanded use in Waldenström's macroglobulinemia
Zanubrutinib is now approved in over 75 markets globally, with 2025 global sales growing nearly 50% year-on-year.
石药集团 (CSPC) – RSV Vaccine
In August 2026, CSPC Pharmaceutical Group received FDA IND clearance for its respiratory syncytial virus (RSV) vaccine candidate, advancing to clinical trials in the U.S. This marks a significant step for Chinese vaccine developers entering the U.S. clinical development pipeline.
康方生物 (Akeso) – Ivonescimab
Akeso's ivonescimab (PD-1/VEGF bispecific antibody) continued to advance globally. In 2026, the drug received FDA breakthrough therapy designation for certain NSCLC indications, accelerating its development pathway in the U.S.
百济神州 / SystImmune – BL-B01D1
While BL-B01D1 (the world's first approved bispecific ADC) was approved in China in June 2026, SystImmune and its partner Bristol-Myers Squibb have initiated FDA registration studies for the drug in multiple tumor types. The drug has received 7 Breakthrough Therapy Designations, including one from the U.S. FDA.
V. What This Means for International Patients
For international patients considering treatment in China, FDA approvals of Chinese drugs offer several key benefits:
- Quality validation: FDA approval is the gold standard for drug quality and efficacy. Chinese drugs with FDA approval meet the same rigorous standards as U.S.-developed therapies.
- Global availability: Drugs approved by the FDA are available worldwide, meaning patients can access Chinese-developed therapies in their home countries.
- Cost advantages: Chinese drugs remain significantly more affordable than their U.S.-developed counterparts, even when approved by the FDA.
- Confidence in Chinese healthcare: The growing list of FDA-approved Chinese drugs demonstrates the maturity and quality of China's biopharmaceutical innovation ecosystem.
VI. Conclusion: A New Era for Chinese Biopharma
The 2026 FDA approvals of Cypsedo® and Langlara® — along with the continued global expansion of zanubrutinib and the advancing FDA pipeline of BL-B01D1 and other candidates — mark a turning point for Chinese biopharmaceutical innovation.
China is no longer just a source of low-cost generics or a partner for out-licensing deals. It is now a full-fledged innovator capable of developing, manufacturing, and commercializing globally competitive therapies in the world's most demanding regulatory environment.
The era of Chinese drugs at the FDA has arrived.